The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: Time for reassessment

Evidence-Based Medicine

Volumn 18, Issue 2, 2013, Pages 44-47

  Fuchs, Flávio Danni ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; META ANALYSIS (TOPIC); REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 85027932616     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2012-100851     Document Type: Review

References (26)

1. Krause T, Lovibond K, Caulfield M, et al. Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA 2003;289:2560-71.
3. Mancia G, Laurent S, Agabiti-Roseic E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58.
4. Fuchs FD. The corporate bias and the molding of prescription practices: the case of hypertension. Braz J Med Biol Res 2009;42:224-8.
5. Dahlöf B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
6. Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 2002;359:2203.
7. Kato J, Eto T. Diuretics in the LIFE study. Lancet 2004;364:413.
8. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
9. Fuchs FD. The ADVANCE trial. Lancet 2008;371:25.
10. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
11. Yusuf S, Teo K, Anderson C, et al. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-83.
12. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37.
13. McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90.
14. Yusuf S, Healey JS, Pogue J, et al. ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38.
15. Haller H, Ito S, Izzo JL Jr,, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
16. Imai E, Chan JC, Ito S, et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011;54:2978-86.
17. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:B1665.
18. Bangalore S, Kumar S, Wetterslev J, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
19. McAlister FA, Renin Angiotension System Modulator Meta-Analysis Investigators. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 2012;33:505-14.
20. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012. [Epub ahead of print].
21. Disertori M, Latini R, Barlera S, et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.
22. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol 2012;5:43-51.
23. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker versus dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension ( J-RHYTHM II Study). Europace 2011;13:473-9.
24. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in Type 1 diabetes. N Engl J Med 2009;361:40-51.
25. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-59.
26. Mann JF, Schmieder RE, Dyal L, et al. TRANSCEND Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151:1-10.